Abstract
Lenalidomide maintenance (LM) starting between 2-3 months after auto HCT until progression is our standard of care for multiple myeloma (MM) patients. We aimed to determine the time to best response and the progression free survival (PFS) impact of improving response on LM.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
